Alligator Bioscience AB (publ) Interim report January-March 2019
First patient dosed in Phase I clinical study of ATOR-1015 Significant events January-March• First patient dosed in Phase I clinical study o ...
Alligator Bioscience AB Year-end Report 2018
The bispecific drug candidate ATOR-1015 in clinical development Significant events October-December• The Swedish MPA (Medical Products Agenc ...
Alligator Bioscience AB Interim Report January-September 2018
The science behind the Nobel Prizes in Medicine and Chemistry constitutes the core in Alligator’s research and development. Significant even ...
Alligator Bioscience AB Interim Report January-June 2018
Positive data for our preclinical projects Significant events April-June• The ADC-1013 clinical phase I study performed by Janssen is ongoin ...
Alligator Bioscience AB Interim Report January-March 2018
Positive preclinical data for ATOR-1015 "Data provide strong support for our claims that ATOR-1015 is a next generation bispecific CTLA- ...
Alligator Bioscience AB Full Year Report 2017
The Janssen collaboration continues, milestone payment of 6 MUSD triggered Significant events, October-December • Alligator Bioscience recor ...
Alligator Bioscience AB Interim Report January-September 2017
Three important collaborations in place. Results in November from ADC-1013 clinical phase I study. Significant events, July-September • Apte ...
Alligator Bioscience AB (Nasdaq Stockholm; ATORX) Interim report January – June 2017
“We have advanced our project pipeline significantly during the second quarter. The immuno-oncology antibody ATOR-1017 moved into pre-clinic ...
Alligator Bioscience AB Interim report January-March 2017
Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today announced its report for the first quarter 2017. “In the first quarte ...